- Home
- EBS vs PRTC Comparison
EBS vs PRTC Comparison
Compare EBS & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- PRTC
- Stock Information
- Founded
- EBS 1998
- PRTC 2015
- Country
- EBS United States
- PRTC United States
- Employees
- EBS N/A
- PRTC N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- PRTC Health Care
- Exchange
- EBS Nasdaq
- PRTC Nasdaq
- Market Cap
- EBS 518.0M
- PRTC 431.0M
- IPO Year
- EBS 2006
- PRTC N/A
- Fundamental
- Price
- EBS $10.20
- PRTC $17.66
- Analyst Decision
- EBS Strong Buy
- PRTC Buy
- Analyst Count
- EBS 3
- PRTC 1
- Target Price
- EBS $14.33
- PRTC $45.00
- AVG Volume (30 Days)
- EBS 1.1M
- PRTC 3.7K
- Earning Date
- EBS 03-04-2025
- PRTC 08-28-2024
- Dividend Yield
- EBS N/A
- PRTC N/A
- EPS Growth
- EBS N/A
- PRTC N/A
- EPS
- EBS N/A
- PRTC N/A
- Revenue
- EBS $1,125,500,000.00
- PRTC $468,000.00
- Revenue This Year
- EBS $6.26
- PRTC N/A
- Revenue Next Year
- EBS $2.42
- PRTC $160.00
- P/E Ratio
- EBS N/A
- PRTC N/A
- Revenue Growth
- EBS 2.05
- PRTC N/A
- 52 Week Low
- EBS $1.42
- PRTC $17.00
- 52 Week High
- EBS $15.10
- PRTC $34.00
- Technical
- Relative Strength Index (RSI)
- EBS 60.60
- PRTC 36.76
- Support Level
- EBS $9.20
- PRTC $17.15
- Resistance Level
- EBS $10.63
- PRTC $18.21
- Average True Range (ATR)
- EBS 0.67
- PRTC 0.39
- MACD
- EBS 0.05
- PRTC -0.03
- Stochastic Oscillator
- EBS 81.86
- PRTC 26.47
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About PRTC PureTech Health plc
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.